Healthcare
Please check out the biopharma industry’s COVID-19 stories that are trending for April 27, 2021.
AstraZeneca and Sanofi announced that their MELODY Phase III trial of nirsevimab hit the primary endpoint in medically attended lower respiratory tract infections (LRTI) caused by RSV in healthy late preterm and term infants.
Sanofi will use its manufacturing capabilities to support the development of 200 million doses of the Moderna COVID-19 vaccine beginning in September.
A new study suggests that many patients with long-term COVID-19 symptoms still experience health issues six months following infection, are survivors with “long haul” disease have a greater risk of dying and use a more significant number of medications than patients who have fully recovered from the virus.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 20, 2021.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Mayo Clinic announced Wednesday that it has launched two new tech venture companies designed to harness artificial intelligence (AI) and medical algorithms and create “software as medical devices” that clinicians can use to improve treatment across different diseases.
The main concern remains the KN95 mask’s regulation and lack of standardization. Also, to know if you can reuse KN95 mask or not, follow this article.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 13, 2021.
While a failed ebola drug helped treat hospitalized COVID-19 patients, the common cold virus could become key in treating advanced unresectable cancers.
PRESS RELEASES